Ganoderma Lucidum(Reishi) in Cancer Treatment

Author:

Sliva Daniel1

Affiliation:

1. Cancer Research Laboratory, Methodist Research Institute, 1800 N Capitol Ave, E504, Indianapolis, IN 46202.

Abstract

The popular edible mushroom Ganoderma lucidum(Reishi) has been widely used for the general promotion of health and longevity in Asian countries. The dried powder of Ganoderma lucidumwas popular as a cancer chemotherapy agent in ancient China. The authors recently demonstrated that Ganoderma luciduminhibits constitutively active transcription factors nuclear factor kappa B (NF-.B) and AP-1, which resulted in the inhibition of expression of urokinasetype plasminogen activator (uPA) and its receptor uPAR. Ganoderma lucidumalso suppressed cell adhesion and cell migration of highly invasive breast and prostate cancer cells, suggesting its potency to reduce tumor invasiveness. Thus, Ganoderma lucidumclearly demonstrates anticancer activity in experiments with cancer cells and has possible therapeutic potential as a dietary supplement for an alternative therapy for breast and prostate cancer. However, because of the availability of Ganoderma lucidum from different sources, it is advisable to test its biologic activity.

Publisher

SAGE Publications

Subject

Complementary and alternative medicine,Oncology

Reference41 articles.

1. Update from Asia: Asian Studies on Cancer Chemoprevention

2. Evaluation of Botanicals and Dietary Supplements Therapy in Cancer Patients

3. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum.

4. 7. Sone Y, Okuda R, Wada N, Kishida E, Misaki A. Structure and antitumor activities of polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agric Biol Chem. 1985;49:2641-2653.

5. 8. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD. Beta-glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol. 1999;163(6):3045-3052.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3